The PBMCs were stimulated with GPC-derived peptides or an irrelevant peptide (AFP364–373) at 1–60 μg/ml and incubated for 5 hr at 37° in AIM V containing 10% fetal calf serum. For intracellular cytokine staining, brefeldin A (10 μg/ml; Alomone Labs, Jerusalem, Israel) was added for the last 3 hr. Dead cells were excluded using 7-amino-actinomycin D (7-AAD; Sigma-Aldrich) staining. Human TLR1 to TLR9 ligands NSC 683864 (Autogen Bioclear, Calne, UK) were added to cell culture to mimic or modify peptide-induced cytokine production. The LAP (TGF-β1)-producing cells were detected upon peptide stimulation after 18 hr using

an ex vivo ELISPOT assay (R&D Systems, Abingdon, UK) as described previously.11 Cells were surface stained with different fluorochrome-linked antibodies to CD3, CD4, (both BD Pharmingen, Oxford, UK), LAP (TGF-β1) (clone 27232; R&D Systems) and Foxp3 (eBioscience, Hatfield, UK) or isotype controls (R&D Systems) and assessed by flow cytometry. An immunological responder was defined as a twofold increase in the frequency of cytokine-producing cells above control peptides or proteins. Apoptosis selleck chemicals and cell death were assessed using annexin V (BD Pharmingen) and 7-AAD staining. The PBMCs were cultured with or without peptides, including vasoactive intestinal peptide (VIP; Bachem, St. Helens, UK; 1 μm), for 5 hr in the presence

or absence of mouse anti-human TGF-β1 IgG1 (50 μg/ml), mouse anti-human isotype control IgG1 (50 μg/ml), different concentrations of rTGF-β1 (R&D Systems) or PBS diluents (negative control). The cells were then stimulated with lipopolysaccharide (LPS; 10 ng/ml) for a further 24 hr. Interleukin-1β (IL-1β), IL-6, regulated on activation, normal T-cell-expressed and secreted (RANTES) and TNF-α concentrations were determined using human FlowCytomix Simplex assays as described by the manufacturer (Bender Medsystem GmbH, Vienna, Austria). CD4 and CD8 T cells were depleted from PBMCs as described by the manufacturer (Dynal, Oslo, Norway). We screened overlapping peptides covering

GPC to identify a peptide ligand with the ability to stimulate LAP (TGF-β1) expression. In brief, PBMCs were stimulated with overlapping GPC-derived Rho peptides (58 fifteen-mer peptides in total) and the expression of membrane-bound LAP (TGF-β1) on CD4+ T cells was analysed using flow cytometry. In these experiments, dead cells were excluded from the assays using 7-AAD staining (data not shown). CD4+ T cells stimulated with GPC81–95 (YQLTARLNMEQLLQS), but not the other 57 GPC peptides, expressed membrane-bound LAP (TGF-β1) (Fig. 1a). The results demonstrate that GPC81–95 peptide, but not an irrelevant peptide (AFP365–373), stimulates LAP (TGF-β1) expression on CD4+ T cells in a dose-dependent manner (Fig. 1b). LAP (TGF-β1) could also be released from the cells by GPC81–95 treatment in a dose-dependent manner as detected by an ex vivo ELISPOT assay (Fig. 1c).